1. Home
  2. DNTH vs INN Comparison

DNTH vs INN Comparison

Compare DNTH & INN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DNTH
  • INN
  • Stock Information
  • Founded
  • DNTH 2015
  • INN 2010
  • Country
  • DNTH United States
  • INN United States
  • Employees
  • DNTH N/A
  • INN N/A
  • Industry
  • DNTH Biotechnology: Pharmaceutical Preparations
  • INN Real Estate Investment Trusts
  • Sector
  • DNTH Health Care
  • INN Real Estate
  • Exchange
  • DNTH Nasdaq
  • INN Nasdaq
  • Market Cap
  • DNTH 565.7M
  • INN 503.9M
  • IPO Year
  • DNTH N/A
  • INN 2011
  • Fundamental
  • Price
  • DNTH $19.50
  • INN $3.92
  • Analyst Decision
  • DNTH Strong Buy
  • INN
  • Analyst Count
  • DNTH 8
  • INN 0
  • Target Price
  • DNTH $54.33
  • INN N/A
  • AVG Volume (30 Days)
  • DNTH 418.5K
  • INN 1.2M
  • Earning Date
  • DNTH 05-08-2025
  • INN 04-30-2025
  • Dividend Yield
  • DNTH N/A
  • INN 8.12%
  • EPS Growth
  • DNTH N/A
  • INN N/A
  • EPS
  • DNTH N/A
  • INN 0.22
  • Revenue
  • DNTH $6,235,000.00
  • INN $731,783,000.00
  • Revenue This Year
  • DNTH N/A
  • INN $4.13
  • Revenue Next Year
  • DNTH N/A
  • INN $2.53
  • P/E Ratio
  • DNTH N/A
  • INN $17.80
  • Revenue Growth
  • DNTH 120.63
  • INN N/A
  • 52 Week Low
  • DNTH $13.37
  • INN $3.57
  • 52 Week High
  • DNTH $32.27
  • INN $7.22
  • Technical
  • Relative Strength Index (RSI)
  • DNTH 53.31
  • INN 28.96
  • Support Level
  • DNTH $18.37
  • INN $3.81
  • Resistance Level
  • DNTH $19.76
  • INN $4.19
  • Average True Range (ATR)
  • DNTH 1.93
  • INN 0.35
  • MACD
  • DNTH 0.45
  • INN -0.04
  • Stochastic Oscillator
  • DNTH 95.93
  • INN 17.59

About DNTH Dianthus Therapeutics Inc.

Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.

About INN Summit Hotel Properties Inc.

Summit Hotel Properties Inc is a U.S.-based hotel investment company focusing on select-service hotels in the upscale and upper-midscale properties in the U.S. Substantially all of Summit's assets are held and operated by its Operating Partnership, Summit Hotel OP, LP, in which the company holds general and limited partnership interests. The firm has one segment in activities related to investing in real estate. Summit's revenue streams include Room and Other hotel operations revenue. Room comprises the majority of total revenues. The firm's hotels are located in various markets, such as corporate offices, retail centers, airports, state capitols, convention centers, and leisure attractions. Summit's hotels operate under brands, including Marriott, Hilton, Hyatt, and Holiday Inn.

Share on Social Networks: